Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting.
Launched by ATMO BIOSCIENCES PTY LTD · May 31, 2021
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new device, called a gas-sensing capsule, that can help doctors identify changes in the bacteria and other microorganisms in the gut. This is important for diagnosing a condition known as small intestinal dysbiosis, which can cause various gastrointestinal symptoms. The study aims to see if this capsule can be effectively used in a regular clinical setting, making it easier for doctors to assess gut health.
To participate in this trial, you must be over 18 years old and have an appointment for an upper gastrointestinal endoscopy at the Princess Alexandra Hospital because of unexplained digestive issues. However, certain conditions will exclude you from participating, such as having recent gastrointestinal surgery, swallowing difficulties, or specific gastrointestinal conditions like radiation enteritis or diverticulitis. If you join the study, you will use the capsule, and your doctors will monitor how well it works in assessing your gut health. This trial is currently recruiting participants, and it provides an opportunity to contribute to important research that may improve future diagnostic methods for gut health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged over 18 years presenting to the Department of Gastroenterology \& Hepatology at the Princess Alexandra Hospital who require and are booked for an upper gastrointestinal endoscopy as part of the routine diagnostic work up of e.g. otherwise unexplained gastrointestinal symptoms.
- Exclusion Criteria:
- • Radiation Enteritis
- • Pregnancy
- • Gastric bezoar
- • Swallowing disorders/dysphagia to food or pills
- • Obese, with BMI over 35
- • Suspected or known strictures of the GI tract
- • Fistulas or physiological/mechanical GI obstruction
- • GI surgery within the past 3 months
- • Diverticultis
- • Patients with implantable or portable electro-mechanical medical devices, e.g. pacemakers
About Atmo Biosciences Pty Ltd
Atmo Biosciences Pty Ltd is an innovative biotechnology company dedicated to advancing healthcare through the development of novel diagnostic tools and therapeutic solutions. Specializing in the use of microbiome-based technologies, Atmo Biosciences focuses on enhancing patient outcomes by providing precise, non-invasive methods for monitoring and treating gastrointestinal health. With a commitment to scientific rigor and collaboration, the company aims to transform the landscape of personalized medicine and empower healthcare professionals with cutting-edge tools that improve patient care and clinical decision-making.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Woolloongabba, Queensland, Australia
Lucknow, Uttar Pradesh, India
Patients applied
Trial Officials
Professor Gerald Holtman, MD, PhD, MBA
Principal Investigator
The University of Queensland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials